Compass shorts hit 38% in a month as earnings loom

COMP shares fell 7.7% this week to $9.00, an almost five-fold larger drop than the median -1.6% move across its closest real estate peers, arriving five days before a Q3 earnings release that has already pulled in a fresh round of target-price cuts.

The short-interest rebuild is the most concrete change in the data this week. Short interest has risen 38% over the past month to 10.3% of the free float, a level ORTEX flags as high. The weekly pace was more modest at around 2.5%, and the daily estimate ticked fractionally lower on October 29, suggesting the build is decelerating rather than accelerating into earnings. Despite that, the absolute level is meaningful: the most recent FINRA fortnightly confirms 57.5 million shares short as of October 15, with days-to-cover at 3.5. Borrow conditions, however, are not tightening to match. The cost to borrow has eased nearly 18% over the past month to just 0.40%, and availability is extremely loose at more than ten times the current short interest, roughly 1,026% of shares outstanding. That combination, a rebuilding short position alongside freely available and cheap borrow, points to deliberate conviction rather than a mechanical squeeze setup. No squeeze pressure exists in the lending market right now.

Options positioning has shifted more cautiously over the same window, though not dramatically so. The put/call ratio moved to 0.53 this week, above its 20-day average of 0.45, a reading roughly one standard deviation elevated. That is a mild tilt toward downside protection rather than anything extreme. The 52-week PCR range runs from 0.05 to 0.66, so the current level sits in the upper half but well off the defensive peak. Worth noting is the sharp step-change in the PCR series around October 12, when it jumped from the low 0.30s to the low 0.50s and has held there. That shift coincided with a cluster of analyst target cuts, and options traders have not reversed it.

The Street has been broadly trimming targets while holding positive ratings. UBS cut to $15 from $17 this week while maintaining Buy. Needham dropped to $12 from $17 on October 16, also keeping Buy. Wells Fargo moved its Equal-Weight target down to $10 from $13 on October 12. Citizens initiated with a Market Outperform and an $11 target on October 14. Zelman upgraded to Outperform on October 21 without a published target. The consensus mean target sits at $13.92 against a $9.00 close, implying around 55% upside on paper, but that figure is being dragged by pre-cut targets from August when multiple analysts raised forecasts after a strong Q2 print. The direction of travel this month is unmistakably downward. Factor scores reinforce the mixed picture: forward EPS revisions rank in the 84th percentile, a genuine positive, while EPS momentum over 30 and 90 days ranks near the bottom of the universe at 7 and 23 respectively. The analyst recommendation divergence score of 95 reflects the wide gap between where the stock trades and where analysts have it valued. The PE multiple has expanded about 16% over 30 days, not because earnings estimates improved, but because the stock price has not fallen as far as estimates have.

Wikipedia attention for Compass registered a z-score of 2.40 against its own 90-day history as of October 21, the highest retail-attention reading in that window. The alt-data disclosure note is clear that this measures attention, not revenue, and none of the three available datasets has been measured to lead the company's reported figures. It is colour, not signal. The spike in page views likely reflects the Zillow lawsuit coverage and the ongoing debate over Compass's Private Exclusives feature, both of which feature in the bear case maintained by analysts who question the 3.2% market share ceiling.

FMR (Fidelity) is the largest institutional holder at 14.2% of shares, having added roughly 1.4 million shares through September 30. BlackRock added 4.9 million shares in the same period to reach 7.3%. Founder and CEO Robert Reffkin holds 2.4% but has been a consistent seller under a 10b5-1 plan, with two disclosed transactions in July and August totalling around $567,000 net. Those are pre-arranged sales, which limits their interpretive value, but they have not been offset by open-market purchases from any insider in the window covered by the EDGAR data.

The specific thing to watch is November 5, when Compass reports Q3 results. The single prior earnings event in the ORTEX history for this ticker was August 4, when the stock moved 9.2% higher the following day and held a 8% gain over five days. Whether a stock trading at $9.00 against targets clustered between $10 and $15, with a 38% short-interest build over the past month, produces a comparable reaction or confirms the bears who have been adding positions since early October is the question the print will answer.